Today's Portrait Highlights

RIEMSER Pharma GmbH

RIEMSER Pharma GmbH, headquartered in Greifswald, Germany, is a midsize pharmaceutical company specialized in marketing and sophisticated life cycle management of specialty drugs for treatment of highly complex and niche disease areas. RIEMSER targets European markets but its products are distributed worldwide by a wide-ranging partner network. Our success and our ability to respond dynamically to new challenges are based on the expertise, experience and commitment of our employees. As Specialty Pharma Company, we specialise in medicinal products for the management of malignant diseases (oncology), infectious diseases (anti-infectives), skin conditions (dermatology)and dental products. Other important segments of our range of products include analgesics, cardiovascular products and OTC medicines.

Steinbeis Transfer Center Personalized Medicine

The Steinbeis Transfer Center Personalized Medicine offers support for: • Development and validation of biomarkers • Biostatistical analyses incl. statistical (machine) learning • Diagnostic assay development, quantitative Lateral Flow Assays • Design of experiments and clinical studies (sample size calculations) • Courses in statistics and statistical software • Functional genomics: transcriptomics, metabolomics, genotyping, sequencing • Consulting on patent applications. Key Areas are: • Personalized, predictive medicine (precision medicine) • Development of diagnostic, prognostic and theragnostic markers

BonAlive Biomaterials Ltd

BonAlive Biomaterials Ltd is a privately held Class III medical device manufacturer that is based in Finland. We manufacture bioactive glass S53P4 based products for bone regeneration and septic bone surgery. For the past 15 years our products have shown unmatched clinical performance in orthopedic and trauma surgery, as well as in spine surgery. At BonAlive we are passionate about improving patient outcome. By providing well-proven and safe bone regeneration products to surgeons world-wide we also save operation costs and time. Our vision is to become the world-leader in providing synthetic biomaterial solutions for the treatment of chronically infected bone.